Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.

Last updated: June 2, 2024
Sponsor: University Hospital Muenster
Overall Status: Completed

Phase

N/A

Condition

Pregnancy Complications

Body Composition

Obesity

Treatment

Procalcitonin-variants ELISA-Assay

Clinical Study ID

NCT05703802
10-AnIt-19
  • Ages > 18
  • All Genders

Study Summary

Procalcitonin is a protein consisting of 116 amino-acids which can rapidly rise under inflammatory conditions and sepsis. More than 20 years ago it has been shown that dipeptidylpeptidase-4 (DPP-4) cleaves procalcitonin from the n-terminus, resulting in a truncated procalcitonin-variant which consists of 114 aminoacids. Within their workgroup the investigators found that the truncated procalcitonin-variant had deleterious effects on vascular integrity during sepsis in mice. However, it is unknown if this applies also in humans. By using an ELISA-assay the investigators want to examine the ratio between native and truncated human procalcitonin during diseases accompanied with hyperprocalcitoninemia and correlate the results with clinical data.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age >18

  • Patients with diagnosis...

  • Sepsis or,

  • SIRS after cardiothoracic surgery or,

  • adipositas or,

  • granulomatosis with polyangiitis/microscopic polyangiitis or,

  • pre-eclampsia

  • healthy control subjects

  • written informed consent

Exclusion

Exclusion Criteria:

  • participation in an interventional study trial within the last 3 months

  • relationship to study investigator

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Procalcitonin-variants ELISA-Assay
Phase:
Study Start date:
February 01, 2022
Estimated Completion Date:
November 01, 2022

Study Description

Procalcitonin is a protein consisting of 116 amino-acids which can rapidly rise under inflammatory conditions and sepsis. More than 20 years ago it has been shown that dipeptidylpeptidase-4 (DPP-4) cleaves procalcitonin from the n-terminus, resulting in a truncated procalcitonin-variant which consists of 114 aminoacids.

Within their workgroup the investigators found that the truncated procalcitonin-variant had deleterious effects on vascular integrity during sepsis in mice: They observed that binding of truncated procalcitonin to the CRLR/RAMP1-receptor on vascular endothelium lead to phosphorylation and destruction of VE-cadherin, an essential part of adherens junctions. Consequently, paracellular leakage of proteins and fluid from blood vessels developed.

It is unknown if these effects also apply to humans. By using an ELISA-assay the investigators want to examine the ratio between native and truncated human procalcitonin during diseases accompanied with hyperprocalcitoninemia and correlate the results with clinical data. Futhermore, they want to examine if the procalcitonin-variants have influence on cytokine levels and surface antigens on immune cells by performing multiplex immunoassays and FACS-analysis.

Connect with a study center

  • University Hospital Münster

    Münster, North Rhine-Westphalia 48147
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.